ASLAN Pharmaceuticals

You are now leaving our web site.
I understand
Phase 1
Phase 2
Anticipated Milestones


ASLAN004IL-13Rα1 inhibitor
Atopic dermatitis

MAD interim data early 2021

MAD completion 1H 2021

ASLAN003DHODH inhibitor
Autoimmune disease

Discovery Programs

AhR antagonist1
1 Aryl hydrocarbon receptor, or AhR, program is being developed in an ASLAN majority-owned joint venture


Phase 1

IL-4R/IL-13R inhibitor with the potential to be first-in-class therapy for atopic dermatitis and asthma

Read more about ASLAN004


Phase 1

Potential to be the most potent oral DHODH inhibitor currently in development for autoimmune disease

Read more about ASLAN003

AhR antagonist


Aryl hydrocarbon receptor (AhR) program being developed in oncology

Read more about AhR antagonist

Therapeutic Areas

We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.

Atopic dermatitis AML (Acute Myeloid Leukemia)

Atopic dermatitis

Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide. Up to one-third of adult atopic dermatitis patients are considered moderate-to-severe, for which currently available therapeutics are limited and management is challenging in the majority of cases.

ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1, with potential to be a best-in-class therapy for atopic dermatitis. ASLAN004 is currently undergoing a phase 1 study for the treatment of atopic dermatitis. The SAD portion of the study was completed in the second quarter of 2019. The MAD portion of the study is ongoing with interim data expected in early 2020, and completion expected in the second half of 2020.

AML (Acute Myeloid Leukemia)

The majority of the total AML population have failed on standard of care chemotherapy in AML or do not respond to chemotherapy, which are termed relapsed/refractory. In 2016, the annual incidence of relapsed/refractory patients is approximately 13,000 patients in the United States, 8,000 in Europe, 5,000 in Japan and 24,000 in China. Survival is age-dependent and survival rates are extremely poor for the elderly. The five-year relative survival rate for AML patients aged 19 years and below is 65% but declines to 50% for patients aged 20 to 49 years, and the survival rate for patients aged 65 years or older is only 6%.

The first-line treatment for patients with AML is a combination of aggressive chemotherapies. However, elderly patients with AML are typically ineligible for aggressive treatment regimens due to the significant toxicity associated with these therapies. The survival of these patients is usually less than one year. Over the past two decades, many compounds have been evaluated in AML patients, however, only three targeted drugs have been approved. Furthermore, these drugs target relatively small subsets of patients, leaving a significant unmet need.

A potent inhibitor of DHODH, ASLAN003 has a potentially differentiated safety profile and may be applicable in broad range of AML patients. Ex-vivo and in-vivo data has shown promising efficacy of ASLAN003 in AML. ASLAN has completed a dose escalation trial testing ASLAN003 as a monotherapy in refractory AML patients, and our observed signs of clinical activity and tolerance leads us to believe that ASLAN003 could be applicable in a broad range of AML patients.